Mostrar el registro sencillo del ítem
Artículo
Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation
dc.creator | Caballero Velázquez, Teresa | es |
dc.creator | Calderón Cabrera, Cristina | es |
dc.creator | López-Corral, L. | es |
dc.creator | Puig, N. | es |
dc.creator | Marquez-Malaver, F. | es |
dc.creator | Pérez-López, E. | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.date.accessioned | 2024-02-08T12:56:05Z | |
dc.date.available | 2024-02-08T12:56:05Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Caballero Velázquez, T., Calderón Cabrera, C., López-Corral, L., Puig, N., Marquez-Malaver, F., Pérez-López, E. y Pérez Simón, J.A. (2020). Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation. Bone Marrow Transplantation, 55 (2), 419-430. https://doi.org/10.1038/s41409-019-0670-6. | |
dc.identifier.issn | 0268-3369 | es |
dc.identifier.issn | 1476-5365 | es |
dc.identifier.uri | https://hdl.handle.net/11441/154938 | |
dc.description.abstract | This multicenter phase I trial was designed to evaluate the safety and efficacy of bortezomib (Bz) as part of both the conditioning regimen and the graft-versus-host disease (GvHD) prophylaxis. Patients received fludarabine, melphalan and Bz (days -9 and -2). GVHD prophylaxis consisted of Bz (days +1, +4, and +7), sirolimus (Siro) from day -5 and tacrolimus (Tk) from -3 (except the first five patients that did not receive Tk). Twenty-five patients with poor prognostic multiple myeloma were included. Eleven out of the 19 patients had high-risk features. Out of the 21 patients evaluable at day +100, 14 were in CR (67%) and 7 (33%) in PR. Cumulative incidence (CI) of nonrelapse mortality at 1 year was 24%. CI of grades 2-4 and 3-4 acute GvHD was 35% and 10%, respectively; CI of chronic GvHD was 35% and 55% at 1 and 2 years, respectively. Overall and event free survival at 2 years were 64% and 31%, respectively. Bz as part of the conditioning regimen and in the combination with Siro/tacrolimus for GvHD prophylaxis is safe and effective allowing an optimal disease control early after transplant and reducing the risk of GvHD. | es |
dc.format | application/pdf | es |
dc.format.extent | 12 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer Nature | es |
dc.relation.ispartof | Bone Marrow Transplantation, 55 (2), 419-430. | |
dc.subject | Stem-cell transplantation | es |
dc.subject | Proteasome inhibitor bortezomib | es |
dc.subject | Term-follow-up | es |
dc.subject | Multiple-myeloma | es |
dc.title | Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/acceptedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | CM10/00161 | es |
dc.relation.projectID | EC10-289 | es |
dc.relation.publisherversion | https://www.nature.com/articles/s41409-019-0670-6 | es |
dc.identifier.doi | 10.1038/s41409-019-0670-6 | es |
dc.journaltitle | Bone Marrow Transplantation | es |
dc.publication.volumen | 55 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 419 | es |
dc.publication.endPage | 430 | es |
dc.contributor.funder | Celgene | es |
dc.contributor.funder | Janssen | es |
dc.contributor.funder | Ministerio de Sanidad y Politica Social | es |
dc.contributor.funder | Ministerio de Sanidad y Politica Social, convocatoria de concesion de ayudas para el fomento de la investigacion clinica independiente 2010 | es |
dc.contributor.funder | Ministry of Health CIBER ONC | es |
dc.contributor.funder | CB16/12/00480 | es |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Efficacy of bortezomib to intensify ... | 745.5Kb | ![]() | Ver/ | |
Este registro aparece en las siguientes colecciones
Este documento está protegido por los derechos de propiedad intelectual e industrial. Sin perjuicio de las exenciones legales existentes, queda prohibida su reproducción, distribución, comunicación pública o transformación sin la autorización del titular de los derechos, a menos que se indique lo contrario.